GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE TO REACH USD 5.4 BILLION BY 2024, GROWING AT A CAGR OF 8% DURING THE FORECAST PERIOD

Healthcare-associated Infectious Disease Diagnostics Market Size, Share, Trends, Analysis Report by Products (Consumables and Diagnostic Analyzers/Instruments Devices), Infections (Urinary Tract Infections, Surgical Site Infections, Hospital-Acquired Pneumonia, Bloodstream Infections, and Other Healthcare-Associated Infections), Tests (Traditional Diagnostics and Molecular Diagnostics), End-Users (Hospitals, Clinics, Ambulatory Surgical Centers (ASCs), and Other End-Users), and Geography (North America, APAC, Europe, Latin America, and Middle East & Africa), Industry Analysis Report, Regional Outlook, Growth Trends, Competitive Landscape, Share & Forecast, 2019–2024

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

290 Pages

icon-table

33 Tables

icon-chart

165 Charts

icon-region

5 Regions

icon-country

17 Countries

icon-company

25 Companies

icon-market

5 Market Segment

HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) USD 5.4 Billion (2024)
CAGR 8% (2019-2024)
Base Year 2018
Historic Year 2013 - 2016
Forecast Year 2019 - 2024
Market Segments Products (Consumables and Diagnostic Analyzers/Instruments Devices), Infections (Urinary Tract Infections, Surgical Site Infections, Hospital-Acquired Pneumonia, Bloodstream Infections, and Other Healthcare-Associated Infections), Tests (Traditional Diagnostics and Molecular Diagnostics), End-Users (Hospitals, Clinics, Ambulatory Surgical Centers (ASCs), and Other End-Users)
Geographic Analysis North America, APAC, Europe, Latin America, and Middle East & Africa
Countries Covered Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa ,South Korea, Spain, Turkey, UK, and US

INDUSTRY INSIGHTS

The growing demand for POC tests for the diagnosis of healthcare-associated infections (HAIs) will have a positive impact on the growth of the market

The global healthcare-associated infectious disease diagnostics market size to reach USD 5.4 billion by 2024 growing at a CAGR of over 8% during the forecast period. The application of molecular diagnostics, especially for HAIs, has steadily progressed from research-based highly complex tests to widespread adoption by a diverse range of end-users. While traditional techniques are being challenged, the development of molecular diagnostic tests offers a variety of advantages such as high accuracy and specificity and perform multiple tests in a single instance.  Molecular diagnostics will become a critical part of hospital-acquired infections testing, especially in the battle against antibiotic resistance. Hence, the adoption of molecular diagnostics is likely to increase at a significant rate due to its high sensitivity, specificity, and accuracy, as well as the capability to deliver results quickly. This adoption of molecular diagnostic testing will have a positive impact on the growth of the overall healthcare-associated infections diagnostics market in the coming years.

The dynamics of the healthcare sector is changing due to ongoing healthcare reforms, increasing economic expenditure, and growing recognition that healthcare services need to be less fragmented and more patient-centric. Point-of-care (POC) diagnostics testing is perceived as one of the ways to achieve patient-centric healthcare and cost-effective treatment for patients. POC tests offer significant benefits over the traditional lab-based tests for diagnosing HAIs. For instance, patients admitted in ICUs and neonates in neonatal intensive care could be benefitted as the test could be performed at the bedside, and immediate results can be obtained. Therefore, the growing demand for POC tests for the diagnosis of HAIs will have a positive impact on the growth of the market during the forecast period. The healthcare-associated infectious disease diagnostics market is expected to grow at a CAGR of over 8% during the period 2018–2024.

HEALTHCARE-ASSOCIATED INFECTIONS DIAGNOSTICS MARKET SEGMENTATION

This research report includes detailed market segmentation by

  • Products
  • Tests
  • End-users
  • Infection
  • Geography

INSIGHTS BY PRODUCTS

The growing awareness of HAIs worldwide is one of the key factors fueling the growth of the consumable segment

The usage of a wide array of reagents and test kits to perform diagnostic tests for diagnosing several HAIs in healthcare settings is a major factor for the growth of the consumables segment. Also, the growing awareness of HAIs worldwide is one of the key factors fueling the growth of the consumable segment. The consumables segment is growing due to the increasing usage of several microbial culture tests, urinalysis, immunoassay tests, and PCR tests in several healthcare settings for diagnosing infectious diseases.

The analyzer segment is growing at a relatively slower pace than the consumables segment as it is capital intensive, and purchasing decisions for analyzers depend on financial resources and budget allocations. However, analyzers used in molecular diagnostic tests and at POC sites are growing at a relatively higher growth rate than clinical laboratory analyzers as end-users are preferring analyzers with high sensitivity and delivering highly accurate results with less turnaround time.

INSIGHTS BY INFECTIONS

Urinary tract infections account for 35−40% of nosocomial infections and occupy the largest share in the overall HAIs category

Urinary tract infections (UTI) account for 35−40% of all nosocomial infections and occupy the largest share in the overall HAIs category. The prevalence of hospital-acquired UTIs is continuously increasing globally. Several technological advancements have enhanced the testing procedures for hospital-acquired UTIs. New diagnostic platforms have improved the accuracy and speed of pathogen identification from primary cultures.  The market is likely to grow at a CAGR of 9% during the forecast period.

Surgical site infections are the most common complications following major gastrointestinal surgeries, affecting between 25 and 40% of patients. The surgical site infections (SSI) segment is growing at a steady rate and is likely to grow at a similar pace during the forecast period. SSIs remain a significant clinical challenge as they are associated with substantial mortality and morbidity and impose severe demands on healthcare resources. 

The prevalence of hospital-acquired pneumonia (HAP) and related deaths is increasing at an alarming rate worldwide. Therefore, there is an increased emphasis on minimizing the occurrence of HAP in healthcare settings. The market is expected to witness fast growth in the coming years due to the development and commercialization of advanced nucleic acid detection tests and advancements in POC testing products for pneumonia. Further, the growing awareness of the benefits of a quick diagnosis of HAP is increasing the demand for HAP diagnostic tests both in developed and developing countries. The segment is expected to grow at a CAGR of over 9% during the forecast period.

INSIGHTS BY TESTS

The market is witnessing widespread uptake of POC diagnostic tests for the diagnosis of several infections in several healthcare settings

The traditional diagnostics segment is growing at a moderate rate. A reliable and accurate diagnosis of HAIs is of utmost importance in healthcare settings. Traditional diagnostic tests are considered as the gold-standard and are widely used to diagnose HAIs. The healthcare-associated infections diagnostics market is witnessing widespread uptake of POC diagnostic tests for the diagnosis of several infections in several healthcare settings such as acute and ambulatory healthcare settings. Therefore, there is a growing need for highly efficient and automated diagnostic tests for diagnosing HAIs, especially antibiotic-resistant microbes.

The molecular diagnostics market segment is growing at a faster rate than the traditional diagnostics segment. This growth can be attributed to multiple advantages and clinically proven superior efficacy of molecular diagnostic tests. The increasing availability of automated and compact analyzers has significantly improved the efficiency and quality of end-user operations. These automated analyzers are designed to meet the high demand for quality diagnostic testing.

INSIGHTS BY END-USERS

Developing countries are 20 times more prone to HAIs risk than developed countries

Hospitals are the major source for HAIs, and many hospitalized patients acquire several pathogenic and non-pathogenic infections during the stay. Most hospitals report central line-associated bloodstream infections, catheter-associated UTIs, and SSIs following surgeries such as heart, abdominal hysterectomy, colon, and knee surgical procedures. The adoption of diagnostic testing for healthcare-associated infections is steadily increasing globally to tackle adverse events related to HAIs and take appropriate decisions on treatments. Therefore, the increase in the number of people with HAIs is encouraging physicians in hospitals to use advanced and rapid diagnostic tests, thereby contributing to the growth of the segment.

Healthcare-associated infections are no longer confined to hospitals. Small and medium-sized clinics, physician offices, and solo practitioners are non-adherent to recommended infection prevention and control procedures. Developing countries have reported 20 times more HAIs risk in clinics than in developed countries. The rapid emergence and prevalence of community-associated infections caused by resistant microbes has been recognized to cause serious infections among patients. Therefore, the high risk of HAIs in clinics and ASCs is expected to drive the healthcare-associated infections diagnostics market.

INSIGHTS BY GEOGRAPHY

The increased uptake of molecular diagnostic testing for diagnosing HAIs is a key reason for the significant market growth

The healthcare-associated infections diagnostics market in North America is likely to witness upward growth in terms of revenue, with key vendors focusing on developing innovative and advanced infectious disease diagnostics products, which will offer efficient results. The US is the major revenue contributor to the global market due to the presence of health coverage and the availability of advanced health infrastructure. With the growing demand for diagnostic devices for HAIs, vendors are focusing on introducing innovative products to cater to the growing demand for advanced diagnostic techniques for HAIs in the US.

Europe accounts for the second-highest market share in the global healthcare-associated infections diagnostics market. Countries such as Germany, France, the UK, Spain, Italy, and Denmark have a high occurrence rate of HAIs. According to the European Centre for Disease Control and Prevention (ECDC), approximately 9 million HAI cases occur across Europe annually. The increased uptake of molecular diagnostic testing for diagnosing HAIs is a key reason for the significant market growth. Germany is the largest healthcare-associated infectious disease diagnostics market in Europe. The presence of a large patient pool, better accessibility to diagnostics services, and established healthcare delivery are contributing to the growth of the market in the country.

The growing demand for traditional culture-based tests and immunoassays is a major driver for the APAC market. Further, the low-cost nature and limited resource availability of performing advanced molecular tests is driving the APAC market. The frequency of ICU-acquired infections is at least 2─3 times higher in low- and middle-income countries than in high-income countries. This can be attributed to poor hygiene practices and the lack of stringent regulatory controls. Newborns are the most vulnerable population for HAIs and are at higher risk of acquiring the healthcare-associated infection in developing countries, with 3 to 20 times higher than in high-income countries.

INSIGHTS BY VENDORS

The healthcare-associated infections diagnostics market is consolidated and is characterized by the presence of several active global, regional, and local players, offering a diverse range of diagnostic analyzers and consumables for diagnosing HAIs.  Global players are focusing on developing innovative products and expanding their product portfolio to remain competitive in the market. They are investing extensively in R&D and product development activities to expand their product portfolio. Key players are also engaged in strategic acquisitions as part of the inorganic growth strategy to improve sales and profit margins. Strategic M&As continue to be an important competitive strategy for key players to expand product offerings, access new technology, or increase market share.

The Healthcare-associated Infectious Disease Diagnostics market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

Market Segmentation by Products

  • Consumables
  • Diagnostic Analyzers/Instruments

Market Segmentation by Infections

  • Urinary Tract Infections Hospitals
  • Surgical Site Infections
  • Hospital-acquired Pneumonia
  • Blood Stream Infections
  • Other Healthcare-associated Infections

Market Segmentation by End-users

  • Hospitals
  • Specialty Orthopedic and Spine Centers
  • ASCs

Market Segmentation by Diagnostic Tests

  • Traditional Diagnostics
  • Molecular Diagnostics

Market Segmentation by Geography

  • North America
    • US
    • Canada
  • APAC
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa

Frequently Asked Questions

What is the market size and CAGR of the Healthcare-associated Infectious Disease Diagnostics Market?

Healthcare-associated infectious disease diagnostics market size to reach USD 5.4 Billion by 2024 growing at a CAGR of over 8% during the forecast period.

What factors are driving the Healthcare-associated Infectious Disease Diagnostics Market?

The growing demand for POC tests for the diagnosis of HAIs will have a positive impact on the growth of the market during the forecast period.

Who are the leading market players in the Healthcare-associated Infectious Disease Diagnostics Market?

Abbott, Becton Dickinson, bioMérieux, Danaher, Hoffmann-La Roche, Meridian Bioscience, and QIAGEN are the leading vendors in the Healthcare-associated Infectious Disease Diagnostics Market

What is the growth of the European HAI market during the forecast period?

Europe accounts for the second-highest market share in the global healthcare-associated infections diagnostics market. Countries such as Germany, France, the UK, Spain, Italy, and Denmark have a high occurrence rate of HAIs.

What is the growth of the Urinary tract infections segment?

Urinary tract infections (UTI) account for 35−40% of all nosocomial infections and occupy the largest share in the overall HAIs category. The prevalence of hospital-acquired UTIs is continuously increasing globally.

Download Free Sample

The healthcare-associated infectious disease diagnostics market is expected to grow at a CAGR of over 8% during the period 2018–2024.

 The following factors are likely to contribute to the growth of the healthcare-associated infections diagnostics market during the forecast period:

  • Growing Penetration of POC Tests for Diagnosing HAIs
  • Strategic Acquisitions
  • Increasing Popularity of Molecular Diagnostic Tests for HAIs
  • Increase in Target Patients with Healthcare-associated Infections

Base Year:                  2018

Forecast Year:           2019–2024

The study considers the present scenario of the healthcare-associated infections diagnostics market and its market dynamics for the period 2018−2024. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply aspects of the market. The report profiles and examines leading companies and other prominent companies operating in the market.

Key Vendors in the Healthcare-associated Infections Diagnostics Market

  • Abbott
    • Business Overview
    • Major Product Offerings
    • Product Portfolio
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • bioMérieux
  • Danaher
  • Hoffmann-La Roche
  • Meridian Bioscience
  • QIAGEN 

Prominent Vendors in the Healthcare-associated Infections Diagnostics Market

  • Accelerate Diagnostics
    • Business Overview
    • Major Product Offerings
    • Product Portfolio
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • Bio-Rad
  • DiaSorin Molecular
  • Luminex
  • OpGen
  • Quidel
  • Thermo Fisher Scientific
  • Trinity Biotech

Other Vendors in the Healthcare-associated Infectious Disease Diagnostics Market

  • Bruker
    • Business Overview
  • Diatherix Eurofins
  • Eiken Chemical
  • Genetic Signature
  • Hologic
  • Humor Diagnostics
  • Immunexpress
  • Response Biomedical
  • Seegene
  • T2 Biosystems

Market Segmentation by Products

  • Consumables
  • Diagnostic Analyzers/Instruments

Market Segmentation by Infections 

  • Urinary Tract Infections Hospitals
  • Surgical Site Infections
  • Hospital-acquired Pneumonia
  • Blood Stream Infections
  • Other Healthcare-associated Infections

Market Segmentation by End-users

  • Hospitals
  • Specialty Orthopedic and Spine Centers
  • ASCs

Market Segmentation by Diagnostic Tests

  • Traditional Diagnostics
  • Molecular Diagnostics

Market Segmentation by Geography

  • North America
    • US
    • Canada
  • APAC
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa

1              Research Methodology

2              Research Objectives

3              Research Process

 

4            Scope & Coverage

4.1         Market Definition

4.1.1      Inclusions

4.1.2      Exclusions

4.2         Base Year

4.3         Scope of the study

4.4         Market Segments

4.4.1      Market Segmentation by Products

4.4.2      Market Segmentation by Healthcare-associated Infections

4.4.3      Market Segmentation by Diagnostic Tests

4.4.4      Market Segmentation by End-users

4.4.5      Market Segmentation by Geography

 

5              Report Assumptions & Caveats

5.1          Key Caveats

5.2          Currency Conversion

5.3          Market Derivation

 

6              Market at a Glance

7              Introduction

7.1          Overview

7.1.1      Causative Organisms of HAIs

7.1.2      Epidemiology of HAIs

 

8              Market Dynamics

8.1          Market Growth Enablers

8.1.1      Technological Advancements in Diagnostic Tools & Assays for HAIs

8.1.2      Increase in Patient Population with HAIs

8.1.3      Growing Popularity of Molecular Diagnostic Tests for HAIs

8.2         Market Growth Restraints

8.2.1      Stringent Regulations to Prevent HAIs in Healthcare Settings

8.2.2      Availability of Sophisticated Mechanisms to Control HAIs

8.2.3      Low Prevalence of HAIs in High-income Nations

8.3         Market Opportunities & Trends

8.3.1      Strategic Acquisitions

8.3.2      High Growth Potential in Low and Middle-income Countries

8.3.3      Growing Penetration of POC Tests to Diagnose HAIs

 

9             Market Landscape

9.1          Market Overview

9.2          Market Size & Forecast

9.3          Five Forces Analysis

9.3.1       Threat of New Entrants

9.3.2       Bargaining Power of Suppliers

9.3.3       Bargaining Power of Buyers

9.3.4       Threat of Substitutes

9.3.5       Competitive Rivalry

 

10           Healthcare-associated Infections Diagnostics Market by Infection Type

10.1        Market Snapshot & Growth Engine

10.2        Market Overview

10.3        Urinary Tract Infections

10.3.1    Market Overview

10.3.2    Market Size & Forecast

10.4       Surgical Site Infections

10.4.1    Market Overview

10.4.2    Market Size & Forecast

10.5       Hospital-acquired Pneumonia

10.5.1    Market Overview

10.5.2    Market Size & Forecast

10.6       BloodStream Infections

10.6.1    Market Overview

10.6.2    Market Size & Forecast

10.7       Gastrointestinal Infections

10.7.1    Market Overview

10.7.2    Market Size & Forecast

10.8       Other Healthcare-associated Infections

10.8.1    Market Overview

10.8.2    Market Size & Forecast

 

11           Healthcare-associated Infections Diagnostics Market by Product Type

11.1        Market Snapshot & Growth Engine

11.2        Market Overview

11.3        Consumables

11.3.1     Market Overview

11.3.2     Market Size & Forecast

11.4        Analyzers/Instruments

11.4.1     Market Overview

11.4.2     Market Size & Forecast

 

12           Healthcare-associated Infections Diagnostics Market by Test Type

12.1        Market Snapshot & Growth Engine

12.2        Market Overview

12.3        Traditional Diagnostics

12.3.1     Market Overview

12.3.2     Market Size & Forecast

12.3.3     Traditional Diagnostics Market Segmentation By Geography

12.4        Molecular Diagnostics

12.4.1     Market Overview

12.4.2     Market Size & Forecast

12.4.3     Molecular Diagnostics Market Segmentation by Geography

 

13           Healthcare-associated Infections Diagnostics Market by End-User Type

13.1        Market Snapshot & Growth Engine

13.2        Market Overview

13.3        Hospitals

13.3.1    Market Overview

13.3.2    Market Size & Forecast

13.4       Clinics

13.4.1    Market Overview

13.4.2    Market Size & Forecast

13.5       ASCs

13.5.1    Market Overview

13.5.2    Market Size & Forecast

13.6       Others

13.6.1    Market Overview

13.6.2    Market Size & Forecast

 

14          Healthcare-associated Infections Diagnostics Market by Geography

14.1        Market Snapshot & Growth Engine

14.2        Market Overview

 

15           North America

15.1        Market Overview

15.2        Market Size & Forecast

15.3        Market Segmentation by Test Type

15.4        Key Countries

15.4.1    US: Healthcare-associated Infections Diagnostics Market Size & Forecast

15.4.2    Canada: Market Size & Forecast

 

16           Europe

16.1        Market Overview

16.2        Market Size & Forecast

16.3        Market Segmentation by Test Type

16.4        Key Countries

16.4.1    Germany: Healthcare-associated Infections Diagnostics Market Size & Forecast

16.4.2    France: Market Size & Forecast

16.4.3    UK: Healthcare-associated Infections Diagnostics Market Size & Forecast

16.4.4    Spain: Market Size & Forecast

16.4.5    Italy: Healthcare-associated Infections Diagnostics Market Size & Forecast

 

17         APAC

17.1       Market Overview

17.2       Market Size & Forecast

17.3       Market Segmentation by Test Type

17.4       Key Countries

17.4.1    Japan: Healthcare-associated Infections Diagnostics Market Size & Forecast

17.4.2    China: Market Size & Forecast

17.4.3    India: Healthcare-associated Infections Diagnostics Market Size & Forecast

17.4.4    South Korea: Market Size & Forecast

17.4.5    Australia: Healthcare-associated Infections Diagnostics Market Size & Forecast

 

18           Latin America

18.1        Market Overview

18.2        Market Size & Forecast

18.3        Market Segmentation by Test Type

18.4        Key Countries

18.4.1     Brazil: Healthcare-associated Infections Diagnostics Market Size & Forecast

18.4.2     Mexico: Market Size & Forecast

 

19          Middle-East & Africa

19.1        Market Overview

19.2        Market Size & Forecast

19.3        Market Segmentation by Test Type

19.4        Key Countries

19.4.1    Turkey: Healthcare-associated Infections Diagnostics Market Size & Forecast

19.4.2    South Africa: Market Size & Forecast

19.4.3    Saudi Arabia: Healthcare-associated Infections Diagnostics Market Size & Forecast

 

20          Competitive Landscape

20.1       Competition Overview

20.2       Market Share Analysis

 

21           Key Company Profiles

21.1        Abbott

21.1.1    Business Overview

21.1.2    Major Product Offerings

21.1.3    Key Strengths

21.1.4    Key Strategies

21.1.5    Key Opportunities

21.2        BD

21.2.1    Business Overview

21.2.2    Major Product Offerings

21.2.3    Key Strengths

21.2.4    Key Strategies

21.2.5    Key Opportunities

21.3        bioMérieux

21.3.1    Business Overview

21.3.2    Major Product Offerings

21.3.3    Key Strengths

21.3.4    Key Strategies

21.3.5    Key Opportunities

21.4        Danaher

21.4.1    Business Overview

21.4.2    Major Product Offerings

21.4.3    Key Strengths

21.4.4    Key Strategies

21.4.5    Key Opportunities

21.5        F. Hoffmann-La Roche

21.5.1    Business Overview

21.5.2    Major Product Offerings

21.5.3    Key Strengths

21.5.4    Key Strategies

21.5.5    Key Opportunities

21.6        Meridian Bioscience

21.6.1    Business Overview

21.6.2    Major Product Offerings

21.6.3    Key Strengths

21.6.4    Key Strategies

21.6.5    Key Opportunities

21.7        QIAGEN

21.7.1    Business Overview

21.7.2    Major Product Offerings

21.7.3    Key Strengths

21.7.4    Key Strategies

21.7.5    Key Opportunities

 

22           Other Prominent Vendors

22.1        Trinity Biotech

22.1.1    Business Overview

22.1.2    Major Product Offerings

22.1.3    Key Strengths

22.1.4    Key Strategies

22.1.5    Key Opportunities

22.2        DiaSorin Molecular

22.2.1    Business Overview

22.2.2    Major Product Offerings

22.2.3    Key Strengths

22.2.4    Key Strategies

22.2.5    Key Opportunities

22.3        OpGen

22.3.1    Business Overview

22.3.2    Major Product Offerings

22.3.3    Key Strengths

22.3.4    Key Strategies

22.3.5    Key Opportunities

22.4        Accelerate Diagnostics

22.4.1    Business Overview

22.4.2    Major Product Offerings

22.4.3    Key Strengths

22.4.4    Key Strategies

22.4.5    Key Opportunities

22.5        Thermo Fisher Scientific

22.5.1    Business Overview

22.5.2    Major Product Offerings

22.5.3    Key Strengths

22.5.4    Key Strategies

22.5.5    Key Opportunities

22.6        Bio-Rad

22.6.1    Business Overview

22.6.2    Major Product Offerings

22.6.3    Key Strengths

22.6.4    Key Strategies

22.6.5    Key Opportunities

22.7        Luminex

22.7.1    Business Overview

22.7.2    Major Product Offerings

22.7.3    Key Strengths

22.7.4    Key Strategies

22.7.5    Key Opportunities

22.8        Quidel

22.8.1    Business Overview

22.8.2    Major Product Offerings

22.8.3    Key Strengths

22.8.4    Key Strategies

22.8.5    Key Opportunities

 

23           Other Vendors

23.1        Genetics Signature

23.1.1    Business Overview

23.2        Seegene

23.2.1    Business Overview

23.3        Diatherix Eurifins

23.3.1    Business Overview

23.4        Immunexpress

23.4.1    Business Overview

23.5        ResponSe Biomedical

23.5.1    Business Overview

23.6        Humor Diagnostics

23.6.1    Business Overview

23.7        Eiken Chemical

23.7.1    Business Overview

23.8        Bruker

23.8.1    Business Overview

23.9        T2 Biosystems

23.9.1    Business Overview

23.10     Hologic

23.10.1  Business Overview

 

24           Report Summary

24.1        Key Takeaways

24.2        Strategic Recommendations

24.3        Quantitative Summary

24.3.1    Market by Product Type

24.3.2    Market by Test Type

24.3.3    Market by Infection Type

24.3.4    Market by End-user Type

24.3.5    Market by Geography

 

25           Appendix

25.1        Abbreviations

               

 

List of Exhibits 

Exhibit 1               Segmentation of Global Healthcare-associated Infectious Disease Diagnostics Market

Exhibit 2               Market Size Calculation Approach 2018

Exhibit 3               Major Causes for the Spread of Healthcare-associated Infections

Exhibit 4               Technological Advancements in Diagnostic Tools & Assays for HAIs

Exhibit 5               Increase in Patient Population with HAIs

Exhibit 6               Growing Popularity of Molecular Diagnostic Tests for HAIs

Exhibit 7               Important Milestones in Molecular Diagnostics for Infectious Diseases

Exhibit 8               Comparison of Blood Culture Test Versus Molecular Diagnostic Test

Exhibit 9               Stringent Regulations to Prevent HAIs in Healthcare Settings

Exhibit 10             WHO’s Recommendations Using My 5 Moments for Hand Hygiene Approach

Exhibit 11             Important Recommendations for Healthcare Settings to Prevent HAIs

Exhibit 12             Availability of Sophisticated Mechanisms to Control HAIs

Exhibit 13             Steps Involved in Reprocessing Cycle of Sterile Supplies

Exhibit 14             Popular Equipment Used in Healthcare Settings to Control HAIs

Exhibit 15             Low Prevalence of HAIs in High-income Nations

Exhibit 16             Rate of HAIs in Europe (Per 1,000 population)

Exhibit 17             Strategic Acquisitions

Exhibit 18             High Growth Potential in Low and Middle-income Countries

Exhibit 19             Emerging Economies Witnessing Higher Absolute Growth in APAC

Exhibit 20             Emerging Economies Witnessing Higher Absolute Growth in Latin America

Exhibit 21             Growing Penetration of POC Tests to Diagnose HAIs

Exhibit 22             Global Healthcare-associated Infectious Disease Diagnostics Market 2018−2024 ($ million)

Exhibit 23             Five Forces Analysis 2018

Exhibit 24             Incremental Growth by Infection Type 2018–2024

Exhibit 25             Global Healthcare-associated Infections Diagnostics Market by Infection Type

Exhibit 26             Market by Infection Type 2018 & 2024 (%)

Exhibit 27             Market by Infection Type 2018−2024 ($ million)

Exhibit 28             Market by Infection Type 2018−2024 (%)

Exhibit 29             Market by Infection Type 2018-2024 (Incremental Growth)

Exhibit 30             Market by Infection Type 2018-2024 (Absolute Growth)

Exhibit 31             Global Healthcare-associated Infections Diagnostics Market by UTIs: Incremental and Absolute Growth Comparison

Exhibit 32             Risk Factors with Development of Hospital-associated UTIs

Exhibit 33             Market by UTIs 2018−2024 ($ million)

Exhibit 34             Hospital-acquired Bacteriuria in Patients with Indwelling Urethral Catheters (%)

Exhibit 35             Global Healthcare-associated Infections Diagnostics Market by SSIs: Incremental and Absolute Growth Comparison

Exhibit 36             Risk Factors of Surgical Site Infections

Exhibit 37             Market by SSIs 2018−2024 ($ million)

Exhibit 38             Global Healthcare-associated Infections Diagnostics Market by HAP: Incremental and Absolute Growth Comparison

Exhibit 39             Common Pathogens Causing HAP

Exhibit 40             Market by HAP 2018−2024 ($ million)

Exhibit 41             Host Risk Factors with Development of Multidrug-resistant Infection in HAP

Exhibit 42             Global Healthcare-associated Infections Diagnostics Market by BSI: Incremental and Absolute Growth Comparison

Exhibit 43             Market by BSI 2018−2024 ($ million)

Exhibit 44             Global Healthcare-associated Infections Diagnostics Market by GII: Incremental & Absolute Growth Comparison

Exhibit 45             Market by GII 2018−2024 ($ million)

Exhibit 46             Global Healthcare-associated Infections Diagnostics by Other Infections Incremental and Absolute Growth Comparison

Exhibit 47             Market by Other Infections 2018−2024 ($ million)

Exhibit 48             Incremental Growth by Product Type 2018–2024

Exhibit 49             Global Healthcare-associated Infections Diagnostics Market by Product Type

Exhibit 50             Market by Product Type 2018 & 2024 (%)

Exhibit 51             Market by Product Type 2018−2024 ($ million)

Exhibit 52             Market by Product Type 2018−2024 (%)

Exhibit 53             Market by Product Type 2018-2024 (Incremental Growth)

Exhibit 54             Market by Product Type 2018-2024 (Absolute Growth)

Exhibit 55             Global Healthcare-associated Infections Diagnostics Market by Consumables: Incremental and Absolute Growth Comparison

Exhibit 56             Market by Consumables 2018−2024 ($ million)

Exhibit 57             Global Healthcare-associated Infections Diagnostics Market by Analyzers/Instruments: Incremental and Absolute Growth Comparison

Exhibit 58             Market by Analyzers/Instruments 2018−2024 ($ million)

Exhibit 59             Incremental Growth by Test Type 2018−2024

Exhibit 60             Global Healthcare-associated Infections Diagnostics Market by Test Type

Exhibit 61             Market by Test Type 2018 & 2024 (%)

Exhibit 62             Market by Test Type 2018-2024 ($ million)

Exhibit 63             Market by Test Type 2018-2024 (%)

Exhibit 64             Market by Test Type 2018-2024 (Incremental Growth)

Exhibit 65             Market by Test Type 2018-2024 (Absolute Growth)

Exhibit 66             Global Traditional Healthcare-associated Infections Diagnostics Market: Incremental and Absolute Growth Comparison

Exhibit 67             Global  Traditional HAI Diagnostics Market 2018−2024 ($ million)

Exhibit 68             Global Traditional HAI Diagnostics Market 2018 & 2024 (%)

Exhibit 69             Global Traditional HAI Diagnostics Market 2018−2024 ($ million)

Exhibit 70             Global Traditional HAI Diagnostics Market 2018−2024 (%)

Exhibit 71             Global Molecular Healthcare-associated Infections Diagnostics Market: Incremental and Absolute Growth Comparison

Exhibit 72             Major Advantages of Molecular Diagnostics

Exhibit 73             Market by Molecular Diagnostics 2018−2024 ($ million)

Exhibit 74             Global Molecular HAI Diagnostics Market 2018 & 2024 (%)

Exhibit 75             Global Molecular HAI Diagnostics Market 2018−2024 ($ million)

Exhibit 76             Global Molecular HAI Diagnostics Market 2018−2024 (%)

Exhibit 77             Incremental Growth by End-user Type 2018−2024

Exhibit 78             Global Healthcare-associated Infections Diagnostics Market by End-user Type

Exhibit 79             Market by End-user Type 2018 & 2024 (%)

Exhibit 80             Market by End-user Type 2018-2024 ($ million)

Exhibit 81             Market by End-user Type 2018-2024 (%)

Exhibit 82             Market by End-user Type 2018-2024 (Incremental Growth)

Exhibit 83             Market by End-user Type 2018-2024 (Absolute Growth)

Exhibit 84             Global Healthcare-associated Infections Diagnostics Market by Hospitals: Incremental and Absolute Growth Comparison

Exhibit 85             Market by Hospitals 2018−2024 ($ million)

Exhibit 86             Market by Clinics: Incremental and Absolute Growth Comparison

Exhibit 87             Market by Clinics 2018−2024 ($ million)

Exhibit 88             Market by ASCs: Incremental and Absolute Growth Comparison

Exhibit 89             Market by ASCs 2018−2024 ($ million)

Exhibit 90             Market by Other End-users: Incremental and Absolute Growth Comparison

Exhibit 91             Market by Other End-users 2018−2024 ($ million)

Exhibit 92             Incremental Growth by Geography 2018−2024

Exhibit 93             Global Healthcare-associated Infections Diagnostics Market by Geography

Exhibit 94             Market by Geography 2018 & 2024 (%)

Exhibit 95             Market by Geography 2018-2024 ($ million)

Exhibit 96             Market by Geography 2018-2024 (%)

Exhibit 97             Market by Geography 2018-2024 (Incremental Growth)

Exhibit 98             Market by Geography 2018-2024 (Absolute Growth)

Exhibit 99             Healthcare-associated Infections Diagnostics Market in North America: Incremental and Absolute Growth Comparison

Exhibit 100          Market in North America 2018–2024 ($ million)

Exhibit 101          North America Market by Test Type 2018 & 2024 (%)

Exhibit 102          North America Market by Test Type 2018–2024 ($ million)

Exhibit 103          North America Market by Test Type 2018–2024 (%)

Exhibit 104          Incremental Growth in North America 2018−2024

Exhibit 105          Market in US 2018–2024 ($ million)

Exhibit 106          Market in Canada 2018–2024 ($ million)

Exhibit 107          Healthcare-associated Infections Diagnostics Market in Europe: Incremental and Absolute Growth Comparison

Exhibit 108          Market in Europe 2018–2024 ($ million)

Exhibit 109          Europe Market by Test Type 2018 & 2024 (%)

Exhibit 110          Europe Market by Test Type 2018–2024 ($ million)

Exhibit 111          Europe Market by Test Type 2018–2024 (%)

Exhibit 112          Incremental Growth in Europe 2018−2024

Exhibit 113          Market in Germany 2018–2024 ($ million)

Exhibit 114          Market in France 2018–2024 ($ million)

Exhibit 115          Market in UK 2018–2024 ($ million)

Exhibit 116          Market in Spain 2018–2024 ($ million)

Exhibit 117          Market in Italy 2018–2024 ($ million)

Exhibit 118          Healthcare-associated Infections Diagnostics Market in APAC: Incremental and Absolute Growth Comparison

Exhibit 119          Market in APAC 2018–2024 ($ million)

Exhibit 120          APAC Market by Test Type 2018 & 2024 (%)

Exhibit 121          APAC Market by Test Type 2018–2024 ($ million)

Exhibit 122          APAC Market by Test Type 2018–2024 (%)

Exhibit 123          Incremental Growth in APAC 2018−2024

Exhibit 124          Market in Japan 2018–2024 ($ million)

Exhibit 125          Market in China 2018–2024 ($ million)

Exhibit 126          Market in India 2018–2024 ($ million)

Exhibit 127          Market in South Korea 2018–2024 ($ million)

Exhibit 128          Market in Australia 2018–2024 ($ million)

Exhibit 129          Healthcare-associated Infections Diagnostics Market in Latin America: Incremental and Absolute Growth Comparison

Exhibit 130          Market in Latin America 2018–2024 ($ million)

Exhibit 131          Latin America Market by Test Type 2018 & 2024 (%)

Exhibit 132          Latin America Market by Test Type 2018–2024 ($ million)

Exhibit 133          Latin America Market by Test Type 2018–2024 (%)

Exhibit 134          Incremental Growth in Latin America 2018−2024

Exhibit 135          Market in Brazil 2018–2024 ($ million)

Exhibit 136          Market in Mexico 2018–2024 ($ million)

Exhibit 137          Healthcare-associated Infections Diagnostics Market in MEA: Incremental and Absolute Growth Comparison

Exhibit 138          Market in MEA 2018–2024 ($ million)

Exhibit 139          MEA Market by Test Type 2018 & 2024 (%)

Exhibit 140          MEA Market by Test Type 2018–2024 ($ million)

Exhibit 141          MEA Market by Test Type 2018–2024 (%)

Exhibit 142          Incremental Growth in MEA 2018−2024

Exhibit 143          Market in Turkey 2018–2024 ($ million)

Exhibit 144          Market in South Africa 2018–2024 ($ million)

Exhibit 145          Market in Saudi Arabia 2018–2024 ($ million)

Exhibit 146          Global Healthcare-associated Infectious Disease Diagnostics Market: Vendors Market Shares

Exhibit 147          Abbott: R&D Expenditure 2016−2018 ($ million)

Exhibit 148          Abbott: Sales Breakdown by Segments in 2017−2018 ($ million)

Exhibit 149          Abbott: Sales Breakdown by Geography 2018 (%)

Exhibit 150          BD: R&D Expenditure 2016−2018 ($ million)

Exhibit 151          BD: Revenue by Business Segments 2017 & 2018 ($ million)

Exhibit 152          BD: Revenue Share by Geography (%)

Exhibit 153          Danaher: R&D Expenditure 2016−2018 ($ million)

Exhibit 154          Danaher: Revenue by Business Segments ($ billion)

Exhibit 155          Danaher: Percentage Share of Revenue by Geographies (%)

Exhibit 156          F. Hoffmann-La Roche: R&D Expenditure 2016−2018 ($ billion)

Exhibit 157          F. Hoffmann-La Roche: Revenue by Business Segments 2017−2018 ($ billion)

Exhibit 158          F. Hoffmann-La Roche: Revenue by Geographies (%)

Exhibit 159          Meridian Bioscience: R&D Expenditure 2016−2018 ($ million)

Exhibit 160          Meridian Bioscience: Revenue by Segments 2017−2018 ($ billion)

Exhibit 161          Meridian Bioscience: Revenue by Geography (%)

Exhibit 162          QIAGEN Revenue 2016−2018 ($ billion)

Exhibit 163          QIAGEN: R&D Expenditure 2016−2018 ($ million)

Exhibit 164          QIAGEN: Revenue by Segments 2017−2018 ($ billion)

Exhibit 165          QIAGEN: Revenue by Geographies

               

List of Tables    

Table 1                  Key Caveats

Table 2                  Currency Conversion 2013−2018

Table 3                  Recent Product Approvals Related to HAI Diagnostics

Table 4                  Popular Acquisitions in Hospital-acquired Infectious Disease Diagnostics Market

Table 5                  Approved Diagnostic Technologies for Diagnosing Hospital-acquired UTIs

Table 6                  Common Microbes Causing GI Infections

Table 7                  Annual Number of Molecular Diagnostic Tests Performed for Various HAIs in 2016

Table 8                  Global Healthcare-associated Infections Diagnostics Market: Vendors Ranking

Table 9                  Abbott: Product Offerings

Table 10               BD: Key Product Offerings

Table 11               bioMérieux: Major Product Offerings

Table 12               Danaher: Key Product Offerings

Table 13               F. Hoffmann-La Roche: Key Product Offerings

Table 14               Meridian Bioscience: Product Offerings

Table 15               QIAGEN: Product Offerings

Table 16               Trinity Biotech: Key Product Offerings

Table 17               DiaSorin Molecular: Key Product Offerings

Table 18               OpGen: Key Product Offerings

Table 19               Accelerate Diagnostics: Key Product Offerings

Table 20               Thermo Fisher Scientific: Key Product Offerings

Table 21               Bio-Rad: Key Product Offerings

Table 22               Luminex: Key Product Offerings

Table 23               Quidel: Key Product Offerings

Table 24               Global Healthcare-associated Infections Market by Products ($ million)

Table 25               Market by Products (%)

Table 26               Global Healthcare-associated Infections Diagnostics Market by Test Type ($ million)

Table 27               Market by Test Type (%)

Table 28               Global Healthcare-associated Infections Diagnostics Market by Infection Type ($ million)

Table 29               Market by Infection Type (%)

Table 30               Global Healthcare-associated Infections Diagnostics Market by End-user Type ($ million)

Table 31               Market by End-user Type (%)

Table 32               Global Healthcare-associated Infections Diagnostics Market by Geography ($ million)

Table 33               Market by Geography (%)

Select a license type that suits your business needs

single-user Single User Licence
$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4000.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date